Reports Q4 revenue $37.4M vs. $41.8M last year. “We are thrilled to begin 2025 with significant momentum. The entire Entrada team has been laser focused on advancing our Duchenne muscular dystrophy franchise, driven by our commitment to bringing a potential best-in-class therapy to patients and their families,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics (TRDA). “The positive data we have presented to date has supported regulatory clearance in multiple geographies for our ELEVATE-44 program and has accelerated the pace at which we are advancing our exon 45, 50 and 51 programs. With a cash runway expected into the second quarter of 2027, we believe we have the people, pipeline and resources to deliver on our bold mission for patients and investors alike.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics Receives Buy Rating Amid Regulatory Progress and Promising Clinical Developments
- Optimistic Outlook on Entrada Therapeutics: FDA Lifts Hold on ENTR-601-44, Paving Way for Key Trials
- Entrada Therapeutics Receives FDA Approval for DMD Study
- Entrada announces FDA removal of clinical hold on ENTR-601-44
- Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks